Clostridium botulinum

Global Botulinum Toxin Market Forecast to 2028 - by Product Type, Application, and End User - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 16, 2022
Health, Biotechnology, Consensus, People, Association, Injection, Time, Neurotoxin, Health care, Society, Consensus decision-making, Male, International Society, BTX, ASPS, Muscle, COVID-19, Overactive bladder, Patient safety, Migraine, CAGR, Paralysis, ANN, Female, Clostridium botulinum, Growth, Plastic, Industry, Spasticity, Bacteria, Hyperhidrosis, American Society of Plastic Surgeons, American Society for Aesthetic Plastic Surgery, Canning, Dentistry, Marketing, Botulinum toxin

The "Botulinum Toxin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Application, and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Botulinum Toxin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Application, and End User" report has been added to ResearchAndMarkets.com's offering.
  • The botulinum toxin market is expected to reach US$ 8,977.62 million by 2028 from US$ 5,307.71 million in 2021.
  • The factors responsible for the botulinum toxin market's growth are increasing aesthetic procedures and the use of botulinum toxin, and the rising number of non-invasive cosmetic procedures.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global botulinum toxin market.

AEON Biopharma Announces the Appointment of Alex Wilson as General Counsel

Retrieved on: 
Wednesday, August 11, 2021
AEON, Industry, Business development, UCLA School of Law, Toxin (comics), Gastroparesis, Patient, Union, Acetylcholine, Physician, United Kingdom, Denervation, Brigham Young University, Arbutus Biopharma, Forward-looking statement, European Union, Clostridium botulinum, 1870 Glaukos, Migraine, General counsel, Associate, Relaxation, EMA, Terminology, SEC, FDA, GLOBE, Marketing, Economics, Neurology, Pharmaceutical industry

NEWPORT BEACH, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications, today announced the appointment of Alex Wilson to the role of General Counsel.

Key Points: 
  • NEWPORT BEACH, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications, today announced the appointment of Alex Wilson to the role of General Counsel.
  • I am proud to join AEON at this exciting time in the companys history.
  • Prior to joining AEON, Alex served as Associate General Counsel, Business Development & Sustainability at Glaukos Corporation.
  • Previously, Alex worked as a corporate attorney in the Newport Beach office of OMelveny & Myers.

Merz and Israeli Start-Up Vensica Launch Partnership for Needleless Treatment of Overactive Bladder

Retrieved on: 
Wednesday, August 11, 2021
Health, Surgery, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Protein, Intention, Therapy, Hypersalivation, Science, Patient, EUR, Blepharospasm, Nocturnal penile tumescence, Torticollis, Neurogenic bladder dysfunction, Yale University, Neurotoxin, Partnership, Merz Aesthetics Women's Challenger, Clostridium botulinum, Interstitial cystitis, Research, Toxin (comics), Multimedia, Anesthesia, Director, Overactive bladder, Board, Merz, Liver disease, Marketing, Movement disorders, Culture, Merz Pharma, Pharmaceutical industry, Medical imaging, Medical device, Merz Therapeutics, Vensica Therapeutics Ltd., Merz, MERZ THERAPEUTICS, VENSICA THERAPEUTICS LTD., MERZ

By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder and interstitial cystitis and other urology indications.

Key Points: 
  • By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder and interstitial cystitis and other urology indications.
  • View the full release here: https://www.businesswire.com/news/home/20210811005052/en/
    Vensicas innovative ultrasound-assisted delivery catheter for the needleless treatment of overactive bladder (Photo: Business Wire)
    Stefan Brinkmann, CEO Merz Therapeutics: This strategic, long-term partnership with the Israeli Start-up Vensica allows us to expand into the attractive market of overactive bladder.
  • Vensica CEO, Avner Geva commented, We are very excited about our strategic partnership with Merz.
  • Merz Group is a global, diversified company based in Frankfurt, Germany, with the three businesses Merz Aesthetics, Merz Therapeutics and Merz Consumer Care.

Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A

Retrieved on: 
Wednesday, June 23, 2021
Biotechnology, Medical devices, Health, Pharmaceutical, Clinical trials, Drugs, Botulism, Gram-positive bacteria, Medical specialties, Clinical medicine, Botulinum toxin, Neurotoxins, Toxins, Merz Pharma, Clostridium botulinum, Merz, Clostridium, Xeomin®, Merz Therapeutics, the Teijin Group, XEOMIN®, MERZ THERAPEUTICS, THE TEIJIN GROUP

Dr. Stefan Albrecht, Senior Vice President Merz Therapeutics Global R&D: This label extension in Japan is another outstanding example for the benefits Xeomin offers to many post-stroke spasticity patients.

Key Points: 
  • Dr. Stefan Albrecht, Senior Vice President Merz Therapeutics Global R&D: This label extension in Japan is another outstanding example for the benefits Xeomin offers to many post-stroke spasticity patients.
  • The highly purified neurotoxin, the only active ingredient in Xeomin, is made by removing complexing proteins from botulinum toxin type A, which is produced by Clostridium botulinum, using purification technology developed by Merz Pharma GmbH & Co. KGaA.
  • Teijin Pharma signed an exclusive license and co-development agreement for Xeomin in Japan with Merz in 2017, and launched exclusive sales of Xeomin in December 2020 after receiving approval granted by Japans Ministry of Health, Labor and Welfare (MHLW).
  • The newly received additional approval for partial changes in the obtained approval based on the phase-III clinical trials conducted by Merz in Japan.

Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Duration Profile Across Multiple Female Age Cohorts

Retrieved on: 
Tuesday, April 27, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Clinical medicine, Medicine, Medical specialties, Botulism, Botulinum toxin, Neurotoxins, Toxins, Clostridium botulinum, Botulinum toxin therapy of strabismus

It is generally accepted that as age increases, the efficacy of botulinum toxin decreases.

Key Points: 
  • It is generally accepted that as age increases, the efficacy of botulinum toxin decreases.
  • This has been demonstrated in multiple studies with current aesthetic botulinum toxin products.
  • A further analysis was performed on female subjects
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.

Botulinum Toxin and Cosmetic Fillers (Children) Bill

Retrieved on: 
Friday, March 5, 2021
Clinical medicine, Medicine, Medical specialties, Botulism, Botulinum toxin, Neurotoxins, Toxins, Botulinum toxin therapy of strabismus, Clostridium botulinum

A Bill to make provision about the administration to persons under the age of 18 of botulinum toxin and of other substances for cosmetic purposes; and for connected purposes.

Key Points: 

A Bill to make provision about the administration to persons under the age of 18 of botulinum toxin and of other substances for cosmetic purposes; and for connected purposes.

China Botulinum Toxin Type A Markets Report, 2015-2019 & 2020-2024 featuring Allergan & Lanzhou Institute of Biological Products

Retrieved on: 
Thursday, February 18, 2021
Botulism, Drugs, Toxins, Botulinum toxin, Neurotoxins, Medical specialties, Clostridium botulinum, Dirk Dressler

In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.

Key Points: 
  • In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.
  • According to this market research, Botulinum Toxin Type A has been growing rapidly since it entered China.
  • As the demand for Botulinum Toxin Type A is expanding, some medical institutions and beauty salons have begun to inject Botulinum Toxin Type A smuggled from South Korea, France, Germany, etc.
  • 2 Sales of Botulinum Toxin Type A in China, 2015-2019
    2.3 Sales of Botulinum Toxin Type A by Dosage Form in China, 2015-2019
    3 Analysis on Major Manufacturers of Botulinum Toxin Type A in China, 2015-2019
    3.3 Lanzhou Institute of Biological Products Co., Ltd.
    3.3.2 Sales of Lanzhou Institute of Biological Products Co., Ltd.'s Botulinum Toxin Type A in China
    4 Prices of Botulinum Toxin Type A in China, 2019-2020
    4.1 Average price of Botulinum Toxin Type A in China, 2019-2020
    4.3 Average price of Lanzhou Institute of Biological Products Co., Ltd.'s Botulinum Toxin Type A (Hengli)
    5 Prospects of China's Botulinum Toxin Type A Market, 2020-2024
    Lanzhou Institute of Biological Products Co., Ltd.

China Botulinum Toxin Type A Investigation Market Report, 2020-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 12, 2020
Pharmaceutical, Health, Other Health, Botulism, Drugs, Toxins, Botulinum toxin, Neurotoxins, Medical specialties, Clostridium botulinum, Draft:List Biological Laboratories

In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.

Key Points: 
  • In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.
  • According to this market research, Botulinum Toxin Type A has been growing rapidly since it entered China.
  • As the demand for Botulinum Toxin Type A is expanding, some medical institutions and beauty salons have begun to inject Botulinum Toxin Type A smuggled from South Korea, France, Germany, etc.
  • 2 Sales of Botulinum Toxin Type A in China, 2015-2019
    2.3 Sales of Botulinum Toxin Type A by Dosage Form in China, 2015-2019
    3 Analysis on Major Manufacturers of Botulinum Toxin Type A in China, 2015-2019
    3.3 Lanzhou Institute of Biological Products Co., Ltd.
    4 Prices of Botulinum Toxin Type A in China, 2019-2020
    4.1 Average price of Botulinum Toxin Type A in China, 2019-2020
    4.3 Average price of Lanzhou Institute of Biological Products Co., Ltd.'s Botulinum Toxin Type A (Hengli)
    5 Prospects of China's Botulinum Toxin Type A Market, 2020-2024
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005665/en/

Teijin Receives Marketing Approval for Merz’s Xeomin® Botulinum Toxin Type A in Japan

Retrieved on: 
Monday, June 29, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Drugs, Botulism, Medical specialties, Branches of biology, Toxins, Botulinum toxin, Neurotoxins, Merz Pharma, Clostridium botulinum, Merz, Antibody, Xeomin®, Merz Therapeutics, the Teijin Group

The highly purified neurotoxin, the only active ingredient in Xeomin, is made by removing complexing proteins from botulinum toxin type A, which is produced by Clostridium botulinum, using purification technology developed by Merz Pharma GmbH & Co. KGaA.

Key Points: 
  • The highly purified neurotoxin, the only active ingredient in Xeomin, is made by removing complexing proteins from botulinum toxin type A, which is produced by Clostridium botulinum, using purification technology developed by Merz Pharma GmbH & Co. KGaA.
  • The lack of complexing proteins enables Xeomin to reduce the production of neutralizing antibodies capable of lowering efficacy.
  • Teijin Pharma signed an exclusive license and co-development agreement for Xeomin in Japan with Merz Pharma GmbH & Co. KGaA in 2017.
  • Therefore, we are very proud of our partnership with Teijin to make Xeomin available to physicians and patients in Japan, said Stefan Brinkmann, CEO Merz Therapeutics.

Emerging Markets Report: Botox, Anthrax, and the Healing Power of Poison

Retrieved on: 
Wednesday, October 2, 2019
Botulism, Drugs, Medicine, Medical specialties, Gram-positive bacteria, Botulinum toxin, Neurotoxins, Clostridium botulinum

How could a product derived from the notorious toxin Clostridium botulinum, the stuff that causes botulism, serve the greater good?

Key Points: 
  • How could a product derived from the notorious toxin Clostridium botulinum, the stuff that causes botulism, serve the greater good?
  • Indeed, U.S. based Spherix Inc. (NASDAQ: SPEX) believes that Anthrax could very well be used to effectively fight ovarian cancer.
  • The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience.
  • Our network consists of stockbrokers, investment bankers, fund managers, journalists and institutions that actively seek opportunities in the micro and small-cap equity markets.